Haleon plc (HLN)vsKiniksa Pharmaceuticals Ltd (KNSA)
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
KNSA
Kiniksa Pharmaceuticals Ltd
$76.27
-0.27%
HEALTHCARE · Cap: $6.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 1226% more annual revenue ($11.15B vs $840.85M). HLN leads profitability with a 14.5% profit margin vs 9.6%. HLN trades at a lower P/E of 20.6x. KNSA earns a higher WallStSmart Score of 53/100 (C-).
HLN
Buy51
out of 100
Grade: C-
KNSA
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HLN.
Margin of Safety
+77.8%
Fair Value
$202.69
Current Price
$76.27
$126.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Revenue surging 55.4% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 30.4% YoY
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Trading at 9.1x book value
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity, EPS Growth. Revenue growth of 55.4% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : KNSA
The primary concerns for KNSA are Price/Book, P/E Ratio. A P/E of 79.3x leaves little room for execution misses.
Key Dynamics to Monitor
HLN profiles as a value stock while KNSA is a hypergrowth play — different risk/reward profiles.
HLN carries more volatility with a beta of 0.24 — expect wider price swings.
KNSA is growing revenue faster at 55.4% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
KNSA scores higher overall (53/100 vs 51/100) and 55.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?